Notice No. 261
Clarify the revenue outlook for fiscal year 2023/24 and the outlook for lower-than-expected operating profit
According to preliminary figures, revenue for the third quarter of 2023/24 was DKK 98.9 million, compared to DKK 298.2 million for the first nine months of 2023/24.
Based on developments in the third quarter of 2023/24 and expectations for the rest of the financial year, our revenue expectations for the 2023/24 financial year are clear. Revenues for 2023/24 are therefore expected to be in the range of DKK 400-415 million versus the previously announced DKK 400-435 million, still within the latest announced range. It will fit.
Earnings in the third quarter of 2023/24 were affected by one-off costs related to organizational changes, which in particular resulted in an operating profit (EBITDA) of DKK 185 million to DKK 200 million in 2023/24. It is expected that. 2023/24 against his previously announced DKK 200-220 million.
The final figures for the third quarter of 2023/24 and the first nine months of 2023/24 will be included in the interim report for the third quarter of 2023/24, to be published on 8 May 2024.
For more information
Niels Huy Nielsen, CFO
Phone number: (+45) 2551 8724
About Kemometech A/S
ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec's equipment is sold to the pharmaceutical, biotech, and agricultural industries around the world. ChemoMetec's customers include some of the world's leading pharmaceutical companies, including Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca, and Johnson & Johnson.
ChemoMetec was founded in 1997 and is listed on the Nasdaq Copenhagen Stock Exchange. For more information, please visit: www.chemometec.com
attachment
